ストックスクリーナーアプリを入手
2.065
5.36%
0.105
前日終値:
$1.96
開ける：
$2.04
24時間の取引高:
1.19M
Relative Volume:
1.55
時価総額：
$145.14M
収益：
$6.96M
当期純損益:
$-46.51M
株価収益率:
-12.03
EPS:
-0.1716
ネットキャッシュフロー:
$-37.99M
1週間 パフォーマンス:
-9.03%
1か月 パフォーマンス:
-25.72%
6か月 パフォーマンス:
-84.37%
1年 パフォーマンス:
-85.86%
1日の値動き範囲:
$1.98
$2.15
1週間の範囲:
$1.90
$2.4051
52週間の値動き範囲:
$1.90
$19.05
Perspective Therapeutics Inc Stock (CATX) Company Profile
名前
Perspective Therapeutics Inc
セクター
電話
509-375-1202
住所
350 Hills Street, Suite 106, Richland
CATX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CATX
Perspective Therapeutics Inc
|
2.065 | 145.14M | 6.96M | -46.51M | -37.99M | -0.1716 |
|
ABT
Abbott Laboratories
|
131.69 | 225.32B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
100.03 | 149.74B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
376.99 | 142.48B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
88.67 | 113.49B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
71.78 | 42.10B | 5.72B | 4.17B | 259.90M | 6.97 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-13 | 開始されました | H.C. Wainwright | Buy |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2024-11-25 | ダウングレード | BofA Securities | Buy → Neutral |
| 2024-10-24 | 開始されました | UBS | Buy |
| 2024-10-01 | 開始されました | Wedbush | Outperform |
| 2024-09-25 | 開始されました | Truist | Buy |
| 2024-07-25 | 開始されました | BofA Securities | Buy |
| 2024-05-09 | 開始されました | Cantor Fitzgerald | Overweight |
すべてを表示
Perspective Therapeutics Inc (CATX) 最新ニュース
Down -16.6% in 4 Weeks, Here's Why Perspective Therapeutics (CATX) Looks Ripe for a Turnaround - Yahoo Finance
Perspective therapeutics CEO Johan Spoor buys $59,672 in stock - Investing.com India
Perspective Therapeutics director Lori Woods acquires $49,999 in stock - Investing.com
Perspective Therapeutics CFO Graham Juan acquires $74,945 in stock By Investing.com - Investing.com UK
Pharma-Biotech Market Development Analysis Report 2025: Growth Opportunities Shaped by a Convergence of Scientific Innovation, Regulatory Evolution, and Market Pressures - GlobeNewswire Inc.
Perspective Therapeutics (NYSE:CATX) Given “Buy” Rating at HC Wainwright - Defense World
Perspective Therapeutics to Participate in Upcoming April Investor Conferences - The Manila Times
Cancer Treatment Innovator Perspective Therapeutics Lines Up Major April Investor Events - Stock Titan
Swiss National Bank Has $275,000 Stock Holdings in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
CATX Q1 EPS Forecast Lowered by Brookline Capital Management - Defense World
Research Analysts Issue Forecasts for CATX Q1 Earnings - Defense World
HighTower Advisors LLC Has $568,000 Position in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Charles Schwab Investment Management Inc. Sells 26,556 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Royal Bank of Canada Issues Pessimistic Forecast for Perspective Therapeutics (NYSE:CATX) Stock Price - Defense World
Bank of New York Mellon Corp Grows Stake in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
RBC Cuts Price Target on Perspective Therapeutics to $15 From $16, Keeps Outperform, Speculative Risk - Marketscreener.com
Perspective Therapeutics earnings missed by $0.37, revenue fell short of estimates - Investing.com Canada
Perspective Therapeutics Reports 2024 Earnings and Clinical Progress - TipRanks
Perspective Therapeutics Inc (CATX) Reports Annual EPS Loss of $1.23, Revenue at $1.5 Million, Surpassing Estimates - GuruFocus.com
Perspective Therapeutics: Expect To Have Sufficient Funding Into Late 2026 - Marketscreener.com
Perspective Therapeutics Secures 2-Year Runway with $227M Cash, Advances Cancer Trials - Stock Titan
CATX stock touches 52-week low at $2.31 amid market fluctuations - Investing.com
What is HC Wainwright’s Forecast for CATX FY2025 Earnings? - Defense World
Brachytherapy Market Expected to Reach USD 1.5 Billion by 2031 | - openPR
HC Wainwright Reiterates “Buy” Rating for Perspective Therapeutics (NYSE:CATX) - Defense World
Perspective Therapeutics (CATX) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Perspective Therapeutics’ (CATX) Outperform Rating Reaffirmed at Wedbush - Defense World
Perspective Flat on New Drug Trials - Baystreet.ca
Perspective Therapeutics Starts Dosing New Cohort for Melanoma Tumor Treatment Therapy - Marketscreener.com
Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma - The Manila Times
Perspective Therapeutics Announces First Patient Dosed With VMT01 In Combination With Nivolumab In A Phase 1/2A Study Of MC1R-Positive Metastatic Melanoma - Marketscreener.com
Perspective Therapeutics, Inc. Initiates First Patient Dosing in Phase 1/2a Trial of [212Pb]VMT01 for Melanoma Treatment - Nasdaq
Breakthrough Melanoma Treatment: New Alpha Therapy Combined With Opdivo Shows Promise - Stock Titan
Bicara Therapeutics Inc (BCAX): A New Perspective - Stocks Register
Analysts Issue Forecasts for CATX Q4 Earnings - Defense World
HC Wainwright Initiates Coverage on Perspective Therapeutics (NYSE:CATX) - Defense World
Dyne Therapeutics Inc (DYN): A New Perspective - Stocks Register
Brookline Capital Management Estimates CATX FY2024 Earnings - The AM Reporter
Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst - Benzinga
HC Wainwright & Co. Initiates Coverage of Perspective Therapeutics (CATX) with Buy Recommendation - Nasdaq
Brokers Set Expectations for CATX FY2024 Earnings - Defense World
Perspective Therapeutics (NYSE:CATX) Stock Rating Upgraded by Brookline Capital Management - Defense World
Perspective Therapeutics at Barclays Healthcare: Radiopharmaceutical Innovations By Investing.com - Investing.com Canada
Brookline Initiates Perspective Therapeutics at Buy With $11 Price Target -March 10, 2025 at 08:33 am EDT - Marketscreener.com
Rhumbline Advisers Has $303,000 Position in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Perspective Therapeutics, Inc. (NYSE:CATX) Given Average Rating of “Buy” by Brokerages - Defense World
Perspective Therapeutics (NYSE:CATX) Research Coverage Started at Scotiabank - Defense World
Perspective Therapeutics (NYSE:CATX) Upgraded at Lifesci Capital - Defense World
Scotiabank Initiates Coverage of Perspective Therapeutics (CATX) with Sector Outperform Recommendation - Nasdaq
Scotiabank starts Perspective Therapeutics with Sector Outperform By Investing.com - Investing.com South Africa
Scotiabank starts Perspective Therapeutics with Sector Outperform - Investing.com
Perspective Therapeutics Inc (CATX) 財務データ
収益
当期純利益
現金流量
EPS
0.44%
0.15%
大文字化:
|
ボリューム (24 時間):